Suvorexant

From MEpedia, a crowd-sourced encyclopedia of ME and CFS science and history
(Redirected from Belsomra)

Suvorexant or Belsomra (brand name) is an orexin receptor antagonist used to treat insomnia and improve sleep. Suvorexant acts as central nervous system depressant.[1][2]

Theory[edit | edit source]

Evidence[edit | edit source]

Clinicians[edit | edit source]

Risks and safety[edit | edit source]

Side effects of suvorexant include interaction with CYP3A inhibitors, increasing their effect.[1][3]

Costs and availability[edit | edit source]

Perscription only controlled drug. Generics not available.

See also[edit | edit source]

Learn more[edit | edit source]

References[edit | edit source]

  1. ↑ 1.0 1.1 "Belsomra - FDA prescribing information, side effects and uses". Drugs.com. Retrieved January 16, 2022.
  2. ↑ Holmberg, Monica (July 10, 2015). "Belsomra". Pharmacy Times. Retrieved January 15, 2022.
  3. ↑ Liu, Mei T. (April 13, 2020). "Current and Emerging Therapies for Insomnia". Am J Manag Care. 26 (4 Suppl): S85–S90.

A chemical that reduces or helps block the activity of another chemical in the body. For example, most antihistamines are H1 antagonists because they block the H1 histamine receptor, which helps relieve allergy symptoms. The opposite of an agonist.[1][2]

antagonist A chemical that reduces or helps block the activity of another chemical in the body. For example, most antihistamines are H1 antagonists because they block the H1 histamine receptor, which helps relieve allergy symptoms. The opposite of an agonist.

adverse reaction Any unintended or unwanted response to a treatment, whether in a clinical trial or licensed treatment. May be minor or serious.

Retrieved from "https://me-pedia.org/w/index.php?title=Suvorexant&oldid=231995"